The aim of the project is to develop and validate a new method to measure proNGF in the cerebrospinal fluid of living patients, and to use it as a biomarker of Alzheimer’s disease (AD). This method, a novel proNGF immunoassay, is based on molecular size separation by capillary electrophoresis and is performed with Simple Wes: this technique produces different immunoreactive peaks whose area can be calculated to search for a quantitative relation with AD. Our purpose was to confirm and validate by mass spectrometry analysis the presence of NGF in the selected peaks